Rapid Fire
Indigenous Antibiotic Nafithromycin
- 21 Nov 2024
- 1 min read
Recently, India launched Nafithromycin, India’s first indigenous antibiotic aimed at tackling Antimicrobial Resistance (AMR).
- Nafithromycin was developed with support from the Biotechnology Industry Research Assistance Council (BIRAC) and brought to market by Wockhardt under the brand name Miqnaf.
- Nafithromycin is the first new antibiotic in its class in over 30 years, marking a breakthrough in the fight against AMR.
- It is designed to treat Community-Acquired Bacterial Pneumonia (CABP), caused by drug-resistant bacteria like Streptococcus pneumoniae.
- The launch coincides with World AMR Awareness Week (18-24 November) 2024 with the theme 'Preventing Antimicrobial Resistance Together'.
Read More: Antimicrobial Resistance
